Research programme: gene-encoded enzyme replacement therapy - SmartPharm Therapeutics
Latest Information Update: 29 Jul 2024
At a glance
- Originator SmartPharm Therapeutics
- Class Gene therapies
- Mechanism of Action Enzyme replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Lysosomal storage diseases
Most Recent Events
- 29 Jul 2024 Preclinical development is ongoing for Lysosomal storage diseases in USA (Parenteral, Injection) (SmartPharm Therapeutics pipeline, July 2024)
- 28 Oct 2023 No recent reports of development identified for preclinical development in Lysosomal storage diseases in USA (Parenteral, Injection)
- 01 Sep 2020 SmartPharm Therapeutics has been acquired by Sorrento Therapeutics